348 related articles for article (PubMed ID: 34749804)
1. The determinants of survival among adults with cystic fibrosis-a cohort study.
Durda-Masny M; Goździk-Spychalska J; John A; Czaiński W; Stróżewska W; Pawłowska N; Wlizło J; Batura-Gabryel H; Szwed A
J Physiol Anthropol; 2021 Nov; 40(1):19. PubMed ID: 34749804
[TBL] [Abstract][Full Text] [Related]
2. Pseudomonas aeruginosa, the type of mutation, lung function, and nutritional status in adults with cystic fibrosis.
John A; Goździk-Spychalska J; Durda-Masny M; Czaiński W; Pawłowska N; Wlizło J; Batura-Gabryel H; Szwed A
Nutrition; 2021 Sep; 89():111221. PubMed ID: 33836428
[TBL] [Abstract][Full Text] [Related]
3. Early childhood lung function is a stronger predictor of adolescent lung function in cystic fibrosis than early Pseudomonas aeruginosa infection.
Pittman JE; Noah H; Calloway HE; Davis SD; Leigh MW; Drumm M; Sagel SD; Accurso FJ; Knowles MR; Sontag MK
PLoS One; 2017; 12(5):e0177215. PubMed ID: 28505188
[TBL] [Abstract][Full Text] [Related]
4. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.
Heltshe SL; Mayer-Hamblett N; Burns JL; Khan U; Baines A; Ramsey BW; Rowe SM;
Clin Infect Dis; 2015 Mar; 60(5):703-12. PubMed ID: 25425629
[TBL] [Abstract][Full Text] [Related]
5. Serum zinc concentration in cystic fibrosis patients with CFTR I1234V mutation associated with pancreatic sufficiency.
AbdulWahab A; Abushahin A; Allangawi M; Chandra P; Abdel Rahman MO; Soliman A
Clin Respir J; 2017 May; 11(3):305-310. PubMed ID: 26096753
[TBL] [Abstract][Full Text] [Related]
6. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.
Rowe SM; Heltshe SL; Gonska T; Donaldson SH; Borowitz D; Gelfond D; Sagel SD; Khan U; Mayer-Hamblett N; Van Dalfsen JM; Joseloff E; Ramsey BW;
Am J Respir Crit Care Med; 2014 Jul; 190(2):175-84. PubMed ID: 24927234
[TBL] [Abstract][Full Text] [Related]
7. CFTR genotype and clinical outcomes of adult patients carried as cystic fibrosis disease.
Bonadia LC; de Lima Marson FA; Ribeiro JD; Paschoal IA; Pereira MC; Ribeiro AF; Bertuzzo CS
Gene; 2014 May; 540(2):183-90. PubMed ID: 24583165
[TBL] [Abstract][Full Text] [Related]
8. Predictors of mortality in adults with cystic fibrosis.
Courtney JM; Bradley J; Mccaughan J; O'Connor TM; Shortt C; Bredin CP; Bradbury I; Elborn JS
Pediatr Pulmonol; 2007 Jun; 42(6):525-32. PubMed ID: 17469153
[TBL] [Abstract][Full Text] [Related]
9. Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation.
Harris JK; Wagner BD; Zemanick ET; Robertson CE; Stevens MJ; Heltshe SL; Rowe SM; Sagel SD
Ann Am Thorac Soc; 2020 Feb; 17(2):212-220. PubMed ID: 31604026
[No Abstract] [Full Text] [Related]
10. Clinical and microbiological characteristics of cystic fibrosis adults never colonized by Pseudomonas aeruginosa: Analysis of the French CF registry.
Vongthilath R; Richaud Thiriez B; Dehillotte C; Lemonnier L; Guillien A; Degano B; Dalphin ML; Dalphin JC; Plésiat P
PLoS One; 2019; 14(1):e0210201. PubMed ID: 30620748
[TBL] [Abstract][Full Text] [Related]
11. DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Viel M; Hubert D; Burgel PR; Génin E; Honoré I; Martinez B; Gaitch N; Chapron J; Kanaan R; Dusser D; Girodon E; Bienvenu T
Clin Respir J; 2016 Nov; 10(6):777-783. PubMed ID: 25763772
[TBL] [Abstract][Full Text] [Related]
12. [Real-world effectiveness of ivacaftor in children with cystic fibrosis and the G551D mutation].
Gomez-Pastrana D; Nwokoro C; McLean M; Brown S; Christiansen N; Pao CS
An Pediatr (Engl Ed); 2019 Mar; 90(3):148-156. PubMed ID: 30093322
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype.
Parad RB; Gerard CJ; Zurakowski D; Nichols DP; Pier GB
Infect Immun; 1999 Sep; 67(9):4744-50. PubMed ID: 10456926
[TBL] [Abstract][Full Text] [Related]
14. Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)-CFTR treated with ivacaftor-Changes in microbiological parameters.
Millar BC; McCaughan J; Rendall JC; Downey DG; Moore JE
J Clin Pharm Ther; 2018 Feb; 43(1):92-100. PubMed ID: 29293275
[TBL] [Abstract][Full Text] [Related]
15. Infections with Pseudomonas aeruginosa in patients with cystic fibrosis.
Tümmler B; Bosshammer J; Breitenstein S; Brockhausen I; Gudowius P; Herrmann C; Herrmann S; Heuer T; Kubesch P; Mekus F; Römling U; Schmidt KD; Spangenberg C; Walter S
Behring Inst Mitt; 1997 Feb; (98):249-55. PubMed ID: 9382747
[TBL] [Abstract][Full Text] [Related]
16. Influence of pancreatic status, CFTR mutations, Staphylococcus aureus and/or Pseudomonas aeruginosa infection/colonization on lung function in cystic fibrosis during a 2-year follow-up period.
Pascoal MA; Marson FAL; Paschoal IA; Levy CE
Wien Klin Wochenschr; 2020 Oct; 132(19-20):572-580. PubMed ID: 32356101
[TBL] [Abstract][Full Text] [Related]
17. Predictors of mucoid Pseudomonas colonization in cystic fibrosis patients.
Levy H; Kalish LA; Cannon CL; García KC; Gerard C; Goldmann D; Pier GB; Weiss ST; Colin AA
Pediatr Pulmonol; 2008 May; 43(5):463-71. PubMed ID: 18361452
[TBL] [Abstract][Full Text] [Related]
18. CFTR genotype as a predictor of prognosis in cystic fibrosis.
McKone EF; Goss CH; Aitken ML
Chest; 2006 Nov; 130(5):1441-7. PubMed ID: 17099022
[TBL] [Abstract][Full Text] [Related]
19. Classic respiratory disease but atypical diagnostic testing distinguishes adult presentation of cystic fibrosis.
Keating CL; Liu X; Dimango EA
Chest; 2010 May; 137(5):1157-63. PubMed ID: 19965956
[TBL] [Abstract][Full Text] [Related]
20. Comparison of radiographic and clinical characteristics of low-risk and high-risk cystic fibrosis genotypes.
Ferril GR; Nick JA; Getz AE; Barham HP; Saavedra MT; Taylor-Cousar JL; Nichols DP; Curran-Everett D; Kingdom TT; Ramakrishnan VR
Int Forum Allergy Rhinol; 2014 Nov; 4(11):915-20. PubMed ID: 25224556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
